Sirolimus Reviews: Side Effects Real Users Report

Sirolimus (rapamycin) is the generic mTOR inhibitor sold as Rapamune. It is FDA-approved for prophylaxis of organ rejection in kidney transplant recipients, taken daily. The related intravenous drug temsirolimus (Torisel) is a prodrug of sirolimus used in oncology; it is a different formulation with a different approved use, and adverse-event patterns reported for one should not be assumed to transfer directly to the other. Everolimus is a third related rapalog. When longevity users or forum posts say "rapamycin," they almost always mean oral sirolimus taken off-label on an intermittent schedule, not the transplant regimen the FDA label describes.

The useful question here is not "does rapamycin cause side effects," which the label already answers for daily transplant dosing, but which patterns reported by off-label weekly users are backed by any controlled comparison, and which are anecdotal signals from a self-selected online population that no trial has yet confirmed or ruled out.

Sirolimus's FDA-approved label, based on daily continuous dosing in transplant recipients, lists mouth ulcers, elevated cholesterol and triglycerides, impaired wound healing, and increased infection risk as known adverse effects. Off-label longevity dosing (weekly or biweekly, well below cumulative transplant exposure) has been studied in only a handful of small trials in healthy older adults, and mechanistic work in rodents suggests intermittent dosing may spare some of the metabolic and immune effects seen with daily dosing. Community reports on r/Longevity, r/Rapamycin, and longevity forums describe a milder version of the label's side-effect list, but these reports come from an unrepresentative, self-selected group and cannot establish true incidence rates on their own.

What is established, what is plausible, and what is not established

Established (from the FDA label, transplant population, daily dosing): hyperlipidemia, mouth ulcers, impaired wound healing, and increased infection risk are documented adverse effects of continuous daily sirolimus in transplant recipients. New-onset diabetes has also been described in this population. These figures reflect a different dose and population than longevity users take, so they should be read as a ceiling on plausible severity, not a direct estimate for weekly dosing.

Plausible but not confirmed at longevity doses: mechanistic and animal data suggest intermittent, once-weekly mTOR inhibition may produce a milder metabolic and immune profile than daily dosing, and small trials in older adults have reported findings consistent with this idea (including a controlled comparison that reported mouth sores as a common adverse event and did not show worse infection outcomes in the treatment arm). The specific effect sizes attributed to any single named trial in online summaries should be verified against the original publication before being treated as fixed numbers; this article intentionally avoids repeating precise percentages that could not be confirmed against a verifiable primary source.

Not established: there is no long-term human outcome data on cardiovascular risk, cancer risk, or mortality from intermittent longevity dosing. There is no controlled trial of the cycling protocols (for example, "8 weeks on, 2 weeks off") that some users describe. Selection bias in online reporting means the true rate of any side effect at longevity doses is unknown, not just imprecisely known.

The gap between transplant data and longevity use

Rapamycin's FDA labeling describes daily dosing in transplant patients, where immunosuppression-related adverse events are expected and monitored closely. Off-label longevity users take a fundamentally different schedule: weekly or biweekly dosing intended to produce intermittent mTOR inhibition rather than sustained suppression. Whether this schedule genuinely changes the risk profile in humans, rather than just delaying or diluting it, has not been settled by long-term controlled data.

Small placebo-controlled trials in healthy older adults have begun testing weekly dosing regimens over periods of roughly a year, and secondary sources describe findings such as a lower rate of clinically reported infections in the treatment arm and mouth sores as the most frequently reported adverse event. Readers should treat any specific percentage attributed to these trials as provisional until checked against the original publication, since inherited citations circulating in longevity content are not reliably matched to the correct paper.

Mouth sores: the most discussed complaint

Across longevity forums, aphthous-type mouth ulcers dominate side-effect discussions. Users describe small, painful lesions on the inner cheeks or tongue appearing a few days after dosing and resolving within about a week. This complaint is also listed in the FDA label for daily dosing and reported as a common adverse event in small controlled trials of weekly dosing in older adults, so it has support at more than one evidence tier, even though the exact incidence at longevity doses is not settled.

A recurring pattern in user reports is that mouth sores correlate with dose escalation: users who jump from 3 mg to 6 mg weekly report earlier or more frequent occurrences than those who titrate slowly. This dose-response pattern is plausible given mTOR's role in cell proliferation, but it has not been tested in a dedicated trial and remains an anecdotal observation, not a confirmed finding.

Lipid changes and metabolic markers

Sirolimus is known to reduce lipoprotein lipase activity and increase hepatic VLDL secretion, a mechanism described in general endocrinology literature on drug-induced dyslipidemia. In the transplant population on daily dosing, hyperlipidemia is a well-documented label effect. At weekly longevity doses, forum users who share bloodwork commonly describe modest LDL increases appearing within a few months of starting, though some report no change at all.

Informal compilations of self-reported lipid panels exist on longevity forums, but these are unverified, non-random samples with no denominator and no comparison group. They can suggest a pattern worth discussing with a prescriber; they cannot substitute for a controlled trial and should not be quoted as an incidence rate.

Wound healing and surgical timing

Rapamycin inhibits fibroblast proliferation, a mechanism well established in transplant medicine and the basis for its use in drug-eluting stent coatings. Kidney transplant literature has associated sirolimus-based immunosuppression with a higher rate of wound complications compared with calcineurin-inhibitor regimens, though the daily transplant dose and immunosuppressed surgical population differ substantially from a healthy adult taking a weekly off-label dose.

Common advice repeated on longevity forums is to pause dosing for a couple of weeks before any planned surgery or dental procedure and to resume only after the site has healed. This is a reasonable precaution given the known mechanism, though the specific "2 weeks" or "4 weeks" windows cited online are community convention rather than a studied protocol.

Immune function: what users track

Sirolimus's mechanism raises an obvious question about infection risk, and it is the side effect longevity users seem to watch most closely. Small trials of weekly dosing in older adults have reported findings that go against the assumption that any mTOR inhibition raises infection risk, with some describing fewer reported infections in the treatment group rather than more. User reports on this point are mixed: some describe fewer colds, others notice no change, and a minority report more frequent cold sores, consistent with the known relationship between mTOR inhibition and herpesvirus reactivation documented in transplant populations.

A related but distinct data point comes from post-marketing safety surveillance of temsirolimus, a related rapalog used intravenously in oncology. A 2026 real-world analysis of adverse event reports for temsirolimus illustrates how spontaneous-report databases surface a different mix of adverse events than pre-approval trials do, with reporting biases in both directions (Temsirolimus real-world adverse event analysis, 2026). This is a useful analogy for interpreting rapamycin forum reports, since both are unverified, self-selected samples, but it is not direct evidence about oral sirolimus in longevity users, and temsirolimus's cancer-population context and IV route make it a poor stand-in for extrapolating specific numbers.

Fatigue and brain fog: signal or noise

A subset of users describe transient fatigue or mental dulling in the day or two after their weekly dose. This complaint appears in a meaningful minority of detailed user logs but is not a prominent finding in the small trials of weekly dosing published so far. Plausible explanations include acute mTORC1 suppression in energy-sensing pathways, a nocebo effect in a highly self-monitoring population, or confounding from other supplements many users take alongside rapamycin (metformin, NAD+ precursors, senolytics). Without a controlled comparison, this remains anecdotal.

Glucose and insulin sensitivity

Daily sirolimus is known to impair glucose tolerance, and new-onset diabetes is listed as a label effect in transplant patients. Rodent studies have reported that intermittent dosing schedules can produce longevity-relevant benefits without the same degree of glucose intolerance seen with daily administration, attributed to transient mTORC1 inhibition without sustained mTORC2 disruption. Whether this rodent finding translates to humans on weekly dosing is plausible but unconfirmed.

User reports broadly track with this distinction: most longevity users who share HbA1c or fasting glucose data report no meaningful change, while a smaller group, often with pre-existing insulin resistance, report modest fasting glucose increases. Standard clinical guidance for patients on mTOR inhibitors recommends monitoring fasting glucose; this guidance was written with daily dosing in mind but is a reasonable precaution for weekly users as well.

Skin and hair effects

A minority of forum users mention mild acne-like eruptions, typically on the chest or back, or slower toenail growth. Hair thinning is mentioned rarely at longevity doses. In transplant patients on daily sirolimus, alopecia has been described in a small percentage of patients; at weekly longevity doses it appears uncommon based on available reports, though there is no controlled study specifically measuring this.

The selection bias problem

Any synthesis of user-reported data has to acknowledge serious limitations. The population posting about rapamycin on Reddit and longevity forums skews heavily toward health-conscious adults taking multiple concurrent interventions (metformin, NAD+ precursors, senolytics), which is not representative of the broader public or of clinical trial populations. Reporting bias can run in either direction: users invested in the longevity hypothesis may underreport problems, while users experiencing side effects may be more motivated to post. The net direction of that bias is not knowable from the forum data itself. Sample sizes in informal compilations are also small, typically dozens of self-selected reporters, compared with the hundreds enrolled in the largest controlled trials of weekly dosing or the much larger transplant registries.

Dose patterns that emerge from user reports

With those limitations in mind, a few patterns recur often enough in forum discussion to note as observations, not conclusions: lower weekly doses (around 3 mg) are more often described as free of noticeable side effects than doses of 5 to 6 mg or higher, where mouth sores become the most frequently mentioned complaint. Above roughly 8 mg weekly, users more often mention lipid changes, fatigue, and delayed healing together. Some users describe cycling schedules, such as extended time off dosing every few months, as a way to manage side effects, but no published trial has tested these specific cycling protocols, so they represent community practice rather than evidence-based dosing.

Evidence review framework: reported experience versus controlled evidence

This table separates what forum and Reddit reports describe from what has actual controlled or label-level support, so a reader can see where a claim sits and what would need to happen before it becomes more than anecdote.

When to seek care rather than wait it out

Persistent or worsening mouth ulcers that interfere with eating, a wound that is not closing or shows signs of infection, unexplained fever, or symptoms of a severe infection warrant prompt medical attention rather than a wait-and-see approach, given rapamycin's known effects on immune function and wound healing. Anyone starting or continuing off-label rapamycin for longevity purposes should be doing so under a clinician who can order baseline and follow-up bloodwork (complete blood count, lipid panel, fasting glucose or HbA1c, and liver function) and who can advise on individual dosing, since this article does not provide individualized dosing guidance.